Lipoprotein a: Where are we now?

Current Opinion in Cardiology

Volumn 24, Issue 4, 2009, Pages 351-357

  Tziomalos, Konstantinos ^a   Athyros, Vasilios G ^b   Wierzbicki, Anthony S ^c   Mikhailidis, Dimitri P ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^c ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

Coronary heart disease; Lipoprotein a; Peripheral arterial disease; Statins; Stroke

Indexed keywords

ACETYLSALICYLIC ACID; ANABOLIC AGENT; ANTIOBESITY AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARDIOVASCULAR AGENT; ESTROGEN; FIBRIC ACID DERIVATIVE; GESTAGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MICROSOMAL TRANSFER PROTEIN INHIBITOR; MIPOMERSEN; NICOTINIC ACID; PROTEIN INHIBITOR; RENIN ANGIOTENSIN SYSTEM INHIBITOR; THYROID HORMONE RECEPTOR BETA AGONIST; UNCLASSIFIED DRUG; HYPOCHOLESTEROLEMIC AGENT;

ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR RISK; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY BLOOD VESSEL; DISEASE COURSE; DRUG EFFECT; DYSLIPIDEMIA; HUMAN; ISCHEMIC HEART DISEASE; OBESITY; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; VASCULAR DISEASE; BLOOD; CORONARY ARTERY DISEASE; FIBRINOLYSIS; INFLAMMATION; PERIPHERAL VASCULAR DISEASES; RISK ASSESSMENT; RISK FACTOR; STROKE;

ANTICHOLESTEREMIC AGENTS; CORONARY ARTERY DISEASE; DISEASE PROGRESSION; FIBRINOLYSIS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION; LIPOPROTEIN(A); PERIPHERAL VASCULAR DISEASES; RISK ASSESSMENT; RISK FACTORS; STROKE;

EID: 67651172948     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/HCO.0b013e32832ac21a     Document Type: Review

References (132)

1. Berglund L, Ramakrishnan R. Lipoprotein(a): an elusive cardiovascular risk factor. Arterioscler Thromb Vasc Biol 2004; 24:2219-2226. (Pubitemid 39658021)
2. Utermann G. The mysteries of lipoprotein(a). Science 1989; 246:904-910.
3. Utermann G, Menzel HJ, Kraft HG, et al. Lp(a) glycoprotein phenotypes. Inheritance and relation to Lp(a)-lipoprotein concentrations in plasma. J Clin Invest 1987; 80:458-465.
4. Scanu AM, Pfaffinger D, Edelstein C. Postprandial Lp(a): identification of a triglyceride-rich particle containing apo E. Chem Phys Lipids 1994; 67- 68:193-198.
5. Nassir F, Bonen DK, Davidson NO. Apolipoprotein(a) synthesis and secretion from hepatoma cells is coupled to triglyceride synthesis and secretion. J Biol Chem 1998; 273:17793-17800. (Pubitemid 28355123)
6. Koschinsky ML, Marcovina SM. Structure-function relationships in apolipoprotein( a): insights into lipoprotein(a) assembly and pathogenicity. Curr Opin Lipidol 2004; 15:167-174.
7. Argraves KM, Kozarsky KF, Fallon JT, et al. The atherogenic lipoprotein Lp(a) is internalized and degraded in a process mediated by the VLDL receptor. J Clin Invest 1997; 100:2170-2181.
8. Lawn RM, Schwartz K, Patthy L. Convergent evolution of apolipoprotein(a) in primates and hedgehog. Proc Natl Acad Sci U S A 1997; 94:11992-11997. (Pubitemid 27467830)
9. Bennet A, Di Angelantonio E, Erqou S, et al. Lipoprotein(a) levels and risk of future coronary heart disease: large-scale prospective data. Arch Intern Med 2008; 168:598-608. An updated meta-analysis of 31 studies evaluating the association of Lp(a) levels with CHD morbidity and mortality in the general population.
10. Smolders B, Lemmens R, Thijs V. Lipoprotein (a) and stroke: a meta-analysis of observational studies. Stroke 2007; 38:1959-1966.
11. Boerwinkle E, Leffert CC, Lin J, et al. Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations. J Clin Invest 1992; 90:52-60.
12. Matthews KA, Sowers MF, Derby CA, et al. Ethnic differences in cardiovascular risk factor burden among middle-aged women: study of Women's Health Across the Nation (SWAN). Am Heart J 2005; 149:1066-1073. (Pubitemid 40848152)
13. Ganotakis ES, Gazi IF, Papadakis JA, et al. The relationship between circulating fibrinogen and lipoprotein (a) levels in patients with primary dyslipidemia. Clin Appl Thromb Hemost 2007; 13:35-42. (Pubitemid 44905281)
14. Ohira T, Schreiner PJ, Morrisett JD, et al. Lipoprotein(a) and incident ischemic stroke: the Atherosclerosis Risk in Communities (ARIC) study. Stroke 2006; 37:1407-1412. (Pubitemid 44305717)
15. Mora S, Cook N, Buring JE, et al. Physical activity and reduced risk of cardiovascular events: potential mediating mechanisms. Circulation 2007; 116:2110-2118. (Pubitemid 350060348)
16. Byrne DJ, Jagroop IA, Montgomery HE, et al. Lipoprotein (a) does not participate in the early acute phase response to training or extreme physical activity and is unlikely to enhance any associated immediate cardiovascular risk. J Clin Pathol 2002; 55:280-285.
17. Kolovou GD, Salpea KD, Anagnostopoulou KK, Mikhailidis DP. Alcohol use, vascular disease, and lipid-lowering drugs. J Pharmacol Exp Ther 2006; 318:1-7. (Pubitemid 43920735)
18. Paassilta M, Kervinen K, Rantala AO, et al. Social alcohol consumption and low Lp(a) lipoprotein concentrations in middle aged Finnish men: population based study. Br Med J 1998; 316:594-595. (Pubitemid 28120992)
19. Papadakis JA, Ganotakis ES, Mikhailidis DP. Beneficial effect of moderate alcohol consumption on vascular disease: myth or reality? J R Soc Health 2000; 120:11-15. (Pubitemid 30213934)
20. Hartmann M, von Birgelen C, Mintz GS, et al. Relation between lipoprotein(a) and fibrinogen and serial intravascular ultrasound plaque progression in left main coronary arteries. J Am Coll Cardiol 2006; 48:446-452. (Pubitemid 44093948)
21. Heinrich J, Sandkamp M, Kokott R, et al. Relationship of lipoprotein(a) to variables of coagulation and fibrinolysis in a healthy population. Clin Chem 1991; 37:1950-1954.
22. Danesh J, Collins R, Peto R. Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies. Circulation 2000; 102:1082-1085.
23. Holmes DT, Schick BA, Humphries KH, Frohlich J. Lipoprotein(a) is an independent risk factor for cardiovascular disease in heterozygous familial hypercholesterolemia. Clin Chem 2005; 51:2067-2073. (Pubitemid 41532622)
24. Kerschdorfer L, Konig P, Neyer U, et al. Lipoprotein(a) plasma concentrations after renal transplantation: a prospective evaluation after 4 years of follow-up. Atherosclerosis 1999; 144:381-391. (Pubitemid 29305472)
25. Marcovina SM, Albers JJ, Scanu AM, et al. Use of a reference material proposed by the International Federation of Clinical Chemistry and Laboratory Medicine to evaluate analytical methods for the determination of plasma lipoprotein(a). Clin Chem 2000; 46:1956-1967.
26. Scanu AM. Lipoprotein(a) further invalidates Friedewald formula. Clin Chem 1994; 40:2115.
27. Pepin JM, O'Neil JA, Hoff HF. Quantification of apo[a] and apoB in human atherosclerotic lesions. J Lipid Res 1991; 32:317-327.
28. Dangas G, Mehran R, Harpel PC, et al. Lipoprotein(a) and inflammation in human coronary atheroma: association with the severity of clinical presentation. J Am Coll Cardiol 1998; 32:2035-2042. (Pubitemid 29010473)
29. Tsimikas S, Tsironis LD, Tselepis AD. New insights into the role of lipoprotein( a)-associated lipoprotein-associated phospholipase A2 in atherosclerosis and cardiovascular disease. Arterioscler Thromb Vasc Biol 2007; 27:2094-2099. (Pubitemid 350287235)
30. Athyros VG, Kakafika AI, Karagiannis A, Mikhailidis DP. Do we need to consider inflammatory markers when we treat atherosclerotic disease? Atherosclerosis 2008; 200:1-12.
31. Syrovets T, Thillet J, Chapman MJ, Simmet T. Lipoprotein(a) is a potent chemoattractant for human peripheral monocytes. Blood 1997; 90:2027-2036. (Pubitemid 27377316)
32. Buechler C, Ullrich H, Aslanidis C, et al. Lipoprotein (a) downregulates lysosomal acid lipase and induces interleukin-6 in human blood monocytes. Biochim Biophys Acta 2003; 1642:25-31. (Pubitemid 37338275)
33. Allen S, Khan S, Tam S, et al. Expression of adhesion molecules by lp(a): a potential novel mechanism for its atherogenicity. FASEB J 1998; 12:1765-1776. (Pubitemid 28553672)
34. Takami S, Yamashita S, Kihara S, et al. Lipoprotein(a) enhances the expression of intercellular adhesion molecule-1 in cultured human umbilical vein endothelial cells. Circulation 1998; 97:721-728. (Pubitemid 28135333)
35. Grainger DJ, Kemp PR, Liu AC, et al. Activation of transforming growth factorbeta is inhibited in transgenic apolipoprotein(a) mice. Nature 1994; 370: 460-462. (Pubitemid 24263550)
36. Grainger DJ, Kirschenlohr HL, Metcalfe JC, et al. Proliferation of human smooth muscle cells promoted by lipoprotein(a). Science 1993; 260:1655-1658. (Pubitemid 23247149)
37. Tsimikas S, Brilakis ES, Miller ER, et al. Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. N Engl J Med 2005; 353:46-57. (Pubitemid 41007806)
38. Kiechl S, Willeit J, Mayr M, et al. Oxidized phospholipids, lipoprotein(a), lipoprotein-associated phospholipase A2 activity, and 10-year cardiovascular outcomes: prospective results from the Bruneck study. Arterioscler Thromb Vasc Biol 2007; 27:1788-1795. (Pubitemid 47207175)
39. Tsimikas S, Kiechl S, Willeit J, et al. Oxidized phospholipids predict the presence and progression of carotid and femoral atherosclerosis and symptomatic cardiovascular disease: five-year prospective results from the Bruneck study. J Am Coll Cardiol 2006; 47:2219-2228. (Pubitemid 43795077)
40. Ichikawa T, Unoki H, Sun H, et al. Lipoprotein(a) promotes smooth muscle cell proliferation and dedifferentiation in atherosclerotic lesions of human apo(a) transgenic rabbits. Am J Pathol 2002; 160:227-236. (Pubitemid 34052283)
41. Hajjar KA, Gavish D, Breslow JL, Nachman RL. Lipoprotein(a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis. Nature 1989; 339:303-305. (Pubitemid 19130696)
42. Miles LA, Fless GM, Levin EG, et al. A potential basis for the thrombotic risks associated with lipoprotein(a). Nature 1989; 339:301-303. (Pubitemid 19130695)
43. Levin EG, Miles LA, Fless GM, et al. Lipoproteins inhibit the secretion of tissue plasminogen activator from human endothelial cells. Arterioscler Thromb 1994; 14:438-442. (Pubitemid 24083861)
44. Etingin OR, Hajjar DP, Hajjar KA, et al. Lipoprotein (a) regulates plasminogen activator inhibitor-1 expression in endothelial cells. A potential mechanism in thrombogenesis. J Biol Chem 1991; 266:2459-2465.
45. Li XN, Grenett HE, Benza RL, et al. Genotype-specific transcriptional regulation of PAI-1 expression by hypertriglyceridemic VLDL and Lp(a) in cultured human endothelial cells. Arterioscler Thromb Vasc Biol 1997; 17: 3215-3223.
46. Ezratty A, Simon DI, Loscalzo J. Lipoprotein(a) binds to human platelets and attenuates plasminogen binding and activation. Biochemistry 1993; 32: 4628-4633. (Pubitemid 23143253)
47. Tsironis LD, Mitsios JV, Milionis HJ, et al. Effect of lipoprotein (a) on platelet activation induced by platelet-activating factor: role of apolipoprotein (a) and endogenous PAF-acetylhydrolase. Cardiovasc Res 2004; 63:130-138.
48. Milionis HJ, Mikhailidis DP, Winder AF. Platelets and lipoprotein (a): a brief overview of their role in the pathogenesis of atherothrombosis. Platelets 1999; 10:277-284.
49. ChironiG, Simon A, Denarie N, et al. Determinants of progression of coronary artery calcifications in asymptomatic men at high cardiovascular risk. Angiology 2002; 53:677-683. (Pubitemid 35340667)
50. Guerra R, Yu Z, Marcovina S, et al. Lipoprotein(a) and apolipoprotein(a) isoforms: no association with coronary artery calcification in the Dallas Heart Study. Circulation 2005; 111:1471-1479.
51. Neil HA, Seagroatt V, Betteridge DJ, et al. Established and emerging coronary risk factors in patients with heterozygous familial hypercholesterolaemia. Heart 2004; 90:1431-1437. (Pubitemid 39626319)
52. Jansen AC, Aalst-Cohen ES, Tanck MW, et al. The contribution of classical risk factors to cardiovascular disease in familial hypercholesterolaemia: data in 2400 patients. J Intern Med 2004; 256:482-490.
53. Nguyen TT, Ellefson RD, Hodge DO, et al. Predictive value of electrophoretically detected lipoprotein(a) for coronary heart disease and cerebrovascular disease in a community-based cohort of 9936 men and women. Circulation 1997; 96:1390-1397.
54. Luc G, Bard JM, Arveiler D, et al. Lipoprotein (a) as a predictor of coronary heart disease: the PRIME Study. Atherosclerosis 2002; 163:377-384. (Pubitemid 34615830)
55. Kamstrup PR, Benn M, Tybaerg-Hansen A, Nordestgaard BG. Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: the Copenhagen City Heart Study. Circulation 2008; 117:176-184. A recent large study showing an independent association between Lp(a) levels and the risk of myocardial infarction in the general population.
56. Uchida T, Inoue T, Kamishirado H, et al. Prediction of short-term progression or regression of atherosclerotic coronary artery disease by lipoprotein (a): a quantitative coronary angiographic study. Angiology 2003; 54:641-646. (Pubitemid 37463260)
57. Berg K, Dahlen G, Christophersen B, et al. Lp(a) lipoprotein level predicts survival and major coronary events in the Scandinavian Simvastatin Survival Study. Clin Genet 1997; 52:254-261. (Pubitemid 28068613)
58. Shlipak MG, Simon JA, Vittinghoff E, et al. Estrogen and progestin, lipoprotein( a), and the risk of recurrent coronary heart disease events after menopause. J Am Med Assoc 2000; 283:1845-1852.
59. Glader CA, Birgander LS, Stenlund H, Dahlen GH. Is lipoprotein(a) a predictor for survival in patients with established coronary artery disease? Results from a prospective patient cohort study in northern Sweden. J Intern Med 2002; 252:27-35. (Pubitemid 34743907)
60. Ridker PM, Hennekens CH, Stampfer MJ. A prospective study of lipoprotein(a) and the risk of myocardial infarction. J Am Med Assoc 1993; 270:2195-2199. (Pubitemid 23323634)
61. Evans RW, Shpilberg O, Shaten BJ, et al. Prospective association of lipoprotein(a) concentrations and apo(a) size with coronary heart disease among men in the Multiple Risk Factor Intervention Trial. J Clin Epidemiol 2001; 54:51-57. (Pubitemid 32109230)
62. Ganotakis ES, Vrentzos GE, Gazi IF, et al. Fibrinogen, lipoprotein (a), albumin and bilirubin (F-L-A-B) levels and cardiovascular risk calculated using the Framingham equation. In Vivo 2007; 21:685-694.
63. Arenillas JF, Molina CA, Chacon P, et al. High lipoprotein (a), diabetes, and the extent of symptomatic intracranial atherosclerosis. Neurology 2004; 63:27-32. (Pubitemid 38943774)
64. Jones GT, van Rij AM, Cole J, et al. Plasma lipoprotein(a) indicates risk for 4 distinct forms of vascular disease. Clin Chem 2007; 53:679-685. (Pubitemid 46580238)
65. Milionis HJ, Winder AF, Mikhailidis DP. Lipoprotein (a) and stroke. J Clin Pathol 2000; 53:487-496.
66. Ariyo AA, Thach C, Tracy R. Lp(a) lipoprotein, vascular disease, and mortality in the elderly. N Engl J Med 2003; 349:2108-2115. (Pubitemid 37464535)
67. Dieplinger B, Lingenhel A, Baumgartner N, et al. Increased serum lipoprotein(a) concentrations and low molecular weight phenotypes of apolipoprotein(a) are associated with symptomatic peripheral arterial disease. Clin Chem 2007; 53:1298-1305. (Pubitemid 47020986)
68. Tzoulaki I, Murray GD, Lee AJ, et al. Inflammatory, haemostatic, and rheological markers for incident peripheral arterial disease: Edinburgh Artery Study. Eur Heart J 2007; 28:354-362. (Pubitemid 46254637)
69. Aboyans V, Criqui MH, Denenberg JO, et al. Risk factors for progression of peripheral arterial disease in large and small vessels. Circulation 2006; 113:2623-2629. (Pubitemid 43948011)
70. Ridker PM, Stampfer MJ, Rifai N. Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. J Am Med Assoc 2001; 285:2481-2485. (Pubitemid 32433842)
71. Pradhan AD, Shrivastava S, Cook NR, et al. Symptomatic peripheral arterial disease in women: nontraditional biomarkers of elevated risk. Circulation 2008; 117:823-831. (Pubitemid 351640684)
72. Smilde TJ, van Wissen S, Wollersheim H, et al. Genetic and metabolic factors predicting risk of cardiovascular disease in familial hypercholesterolemia. Neth J Med 2001; 59:184-195. (Pubitemid 32913050)
73. Sofi F, Marcucci R, Giusti B, et al. High levels of homocysteine, lipoprotein (a) and plasminogen activator inhibitor-1 are present in patients with abdominal aortic aneurysm. Thromb Haemost 2005; 94:1094-1098. (Pubitemid 41645954)
74. Paraskevas KI, Hamilton G, Cross JM, Mikhailidis DP. Atherosclerotic renal artery stenosis: association with emerging vascular risk factors. Nephron Clin Pract 2008; 108:c56-c66. (Pubitemid 351253446)
75. Gazzaruso C, Garzaniti A, Falcone C, et al. Association of lipoprotein(a) levels and apolipoprotein(a) phenotypes with coronary artery disease in type 2 diabetic patients and in nondiabetic subjects. Diabet Med 2001; 18:589-594. (Pubitemid 32823085)
76. Gazzaruso C, Garzaniti A, Giordanetti S, et al. Assessment of asymptomatic coronary artery disease in apparently uncomplicated type 2 diabetic patients: a role for lipoprotein(a) and apolipoprotein(a) polymorphism. Diabetes Care 2002; 25:1418-1424. (Pubitemid 41071155)
77. Tseng CH. Lipoprotein(a) is an independent risk factor for peripheral arterial disease in Chinese type 2 diabetic patients in Taiwan. Diabetes Care 2004; 27:517-521.
78. Hernandez C, Francisco G, Chacon P, Simo R. Lipoprotein(a) as a risk factor for cardiovascular mortality in type 2 diabetic patients: a 10-year follow-up study. Diabetes Care 2005; 28:931-933. (Pubitemid 40434500)
79. Hiraga T, Kobayashi T, Okubo M, et al. Prospective study of lipoprotein(a) as a risk factor for atherosclerotic cardiovascular disease in patients with diabetes. Diabetes Care 1995; 18:241-244.
80. Efstratiadis G, Tziomalos K, Mikhailidis DP, et al. Atherogenesis in renal patients: a model of vascular disease? Curr Vasc Pharmacol 2008; 6:93-107.
81. Athyros VG, Mikhailidis DP, Liberopoulos EN, et al. Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome: a subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) Study. Nephrol Dial Transplant 2007; 22:118-127.
82. Athyros VG, Mikhailidis DP, Papageorgiou AA, et al. The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study. J Clin Pathol 2004; 57:728-734. (Pubitemid 38901488)
83. Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351:1296-1305. (Pubitemid 39268908)
84. Sechi LA, Zingaro L, De Carli S, et al. Increased serum lipoprotein(a) levels in patients with early renal failure. Ann Intern Med 1998; 129:457-461. (Pubitemid 28428081)
85. Muntner P, Hamm LL, Kusek JW, et al. The prevalence of nontraditional risk factors for coronary heart disease in patients with chronic kidney disease. Ann Intern Med 2004; 140:9-17. (Pubitemid 38055916)
86. Kronenberg F, Konig P, Neyer U, et al. Multicenter study of lipoprotein(a) and apolipoprotein(a) phenotypes in patients with end-stage renal disease treated by hemodialysis or continuous ambulatory peritoneal dialysis. J Am Soc Nephrol 1995; 6:110-120.
87. Longenecker JC, Klag MJ, Marcovina SM, et al. High lipoprotein(a) levels and small apolipoprotein(a) size prospectively predict cardiovascular events in dialysis patients. J Am Soc Nephrol 2005; 16:1794-1802.
88. Iliescu EA, Marcovina SM, Morton AR, et al. Apolipoprotein(a) phenotype and lipoprotein(a) level predict peritoneal dialysis patient mortality. Perit Dial Int 2002; 22:492-499.
89. Song KH, Ko SH, Kim HW, et al. Prospective study of lipoprotein(a) as a risk factor for deteriorating renal function in type 2 diabetic patients with overt proteinuria. Diabetes Care 2005; 28:1718-1723. (Pubitemid 40923083)
90. Chien KL, Hsu HC, Su TC, et al. Lipoprotein(a) and cardiovascular disease in ethnic Chinese: the Chin-Shan Community Cardiovascular Cohort Study. Clin Chem 2008; 54:285-291. A recent study showing that Lp(a) concentration above the 95th percentile is a risk factor for stroke and all-cause mortality but not for CHD in the general Chinese population.
91. Paultre F, Pearson TA, Weil HF, et al. High levels of Lp(a) with a small apo(a) isoform are associated with coronary artery disease in African American and white men. Arterioscler Thromb Vasc Biol 2000; 20:2619-2624.
92. Sharrett AR, Ballantyne CM, Coady SA, et al. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation 2001; 104:1108-1113.
93. Anand SS, Yusuf S, Vuksan V, et al. Differences in risk factors, atherosclerosis, and cardiovascular disease between ethnic groups in Canada: the Study of Health Assessment and Risk in Ethnic groups (SHARE). Lancet 2000; 356:279-284. (Pubitemid 30459585)
94. Kamath SK, Hussain EA, Amin D, et al. Cardiovascular disease risk factors in 2 distinct ethnic groups: Indian and Pakistani compared with American premenopausal women. Am J Clin Nutr 1999; 69:621-631. (Pubitemid 29193385)
95. Bhatnagar D, Anand IS, Durrington PN, et al. Coronary risk factors in people from the Indian subcontinent living in west London and their siblings in India. Lancet 1995; 345:405-409.
96. Tziomalos K, Weerasinghe CN, Mikhailidis DP, Seifalian AM. Vascular risk factors in South Asians. Int J Cardiol 2008; 128:5-16.
97. Mohan V, Deepa R, Haranath SP, et al. Lipoprotein(a) is an independent risk factor for coronary artery disease in NIDDM patients in South India. Diabetes Care 1998; 21:1819-1823.
98. Nishtar S, Wierzbicki AS, Lumb PJ, et al. Waist-hip ratio and low HDL predict the risk of coronary artery disease in Pakistanis. Curr Med Res Opin 2004; 20:55-62. (Pubitemid 38063456)
99. Geethanjali FS, Luthra K, Lingenhel A, et al. Analysis of the apo(a) size polymorphism in Asian Indian populations: association with Lp(a) concentration and coronary heart disease. Atherosclerosis 2003; 169:121-130. (Pubitemid 36830930)
100. Sharobeem KM, Patel JV, Ritch AE, et al. Elevated lipoprotein (a) and apolipoprotein B to AI ratio in South Asian patients with ischaemic stroke. Int J Clin Pract 2007; 61:1824-1828.
101. Enas EA, Chacko V, Senthilkumar A, et al. Elevated lipoprotein(a): a genetic risk factor for premature vascular disease in people with and without standard risk factors: a review. Dis Mon 2006; 52:5-50.
102. Meinertz H, Nilausen K, Hilden J. Alcohol-extracted, but not intact, dietary soy protein lowers lipoprotein(a) markedly. Arterioscler Thromb Vasc Biol 2002; 22:312-316. (Pubitemid 34127045)
103. Sacks FM, Lichtenstein A, Van Horn L, et al. Soy protein, isoflavones, and cardiovascular health: an American Heart Association Science Advisory for professionals from the Nutrition Committee. Circulation 2006; 113:1034-1044. (Pubitemid 43879479)
104. Gonbert S, Malinsky S, Sposito AC, et al. Atorvastatin lowers lipoprotein(a) but not apolipoprotein(a) fragment levels in hypercholesterolemic subjects at high cardiovascular risk. Atherosclerosis 2002; 164:305-311. (Pubitemid 35223081)
105. van Wissen S, Smilde TJ, Trip MD, et al. Long term statin treatment reduces lipoprotein(a) concentrations in heterozygous familial hypercholesterolaemia. Heart 2003; 89:893-896.
106. Goudevenos JA, Bairaktari ET, Chatzidimou KG, et al. The effect of atorvastatin on serum lipids, lipoprotein(a) and plasma fibrinogen levels in primary dyslipidaemia: a pilot study involving serial sampling. Curr Med Res Opin 2001; 16:269-275.
107. Rodenburg J, Vissers MN, Wiegman A, et al. Oxidized low-density lipoprotein in children with familial hypercholesterolemia and unaffected siblings: effect of pravastatin. J Am Coll Cardiol 2006; 47:1803-1810.
108. Choi SH, Chae A, Miller E, et al. Relationship between biomarkers of oxidized low-density lipoprotein, statin therapy, quantitative coronary angiography, and atheroma: volume observations from the REVERSAL (Reversal of Atherosclerosis with Aggressive Lipid Lowering) study. J Am Coll Cardiol 2008; 52:24-32.
109. Nair DR, Papadakis JA, Jagroop IA, et al. Statins and fibrinogen. Lancet 1998; 351:1430-1432.
110. Tsimikas S, Witztum JL, Miller ER, et al. High-dose atorvastatin reduces total plasma levels of oxidized phospholipids and immune complexes present on apolipoprotein B-100 in patients with acute coronary syndromes in the MIRACL trial. Circulation 2004; 110:1406-1412. (Pubitemid 39238018)
111. von Eckardstein A, Schulte H, Cullen P, Assmann G. Lipoprotein(a) further increases the risk of coronary events in men with high global cardiovascular risk. J Am Coll Cardiol 2001; 37:434-439. (Pubitemid 32147250)
112. Kronenberg F, Kronenberg MF, Kiechl S, et al. Role of lipoprotein(a) and apolipoprotein(a) phenotype in atherogenesis: prospective results from the Bruneck study. Circulation 1999; 100:1154-1160. (Pubitemid 29426589)
113. Maher VM, Brown BG, Marcovina SM, et al. Effects of lowering elevated LDL cholesterol on the cardiovascular risk of lipoprotein(a). J Am Med Assoc 1995; 274:1771-1774.
114. Mikhailidis DP, Ganotakis ES, Spyropoulos KA, et al. Prothrombotic and lipoprotein variables in patients attending a cardiovascular risk management clinic: response to ciprofibrate or lifestyle advice. Int Angiol 1998; 17:225-233.
115. Rizos E, Bairaktari E, Ganotakis E, et al. Effect of ciprofibrate on lipoproteins, fibrinogen, renal function, and hepatic enzymes. J Cardiovasc Pharmacol Ther 2002; 7:219-226. (Pubitemid 35471357)
116. Athyros VG, Tziomalos K, Mikhailidis DP, et al. Do we need a statin-nicotinic acid-aspirin mini-polypill to treat combined hyperlipidaemia? Expert Opin Pharmacother 2007; 8:2267-2277.
117. Scanu AM, Bamba R. Niacin and lipoprotein(a): facts, uncertainties, and clinical considerations. Am J Cardiol 2008; 101:44B-47B.
118. Merki E, Graham MJ, Mullick AE, et al. Antisense oligonucleotide directed to human apolipoprotein B-100 reduces lipoprotein(a) levels and oxidized phospholipids on human apolipoprotein B-100 particles in lipoprotein(a) transgenic mice. Circulation 2008; 118:743-753.
119. Akaike M, Azuma H, Kagawa A, et al. Effect of aspirin treatment on serum concentrations of lipoprotein(a) in patients with atherosclerotic diseases. Clin Chem 2002; 48:1454-1459. (Pubitemid 34925781)
120. Ranga GS, Kalra OP, Tandon H, et al. Effect of aspirin on lipoprotein(a) in patients with ischemic stroke. J Stroke Cerebrovasc Dis 2007; 16:220-224. (Pubitemid 47369195)
121. Rizos E, Bairaktari E, Kostoula A, et al. The combination of nebivolol plus pravastatin is associated with a more beneficial metabolic profile compared to that of atenolol plus pravastatin in hypertensive patients with dyslipidemia: a pilot study. J Cardiovasc Pharmacol Ther 2003; 8:127-134. (Pubitemid 36701937)
122. Papadakis JA, Ganotakis ES, Jagroop IA, et al. Effect of hypertension and its treatment on lipid, lipoprotein(a), fibrinogen, and bilirubin levels in patients referred for dyslipidemia. Am J Hypertens 1999; 12:673-681.
123. Suk Danik J, Rifai N, Buring JE, Ridker PM. Lipoprotein(a), hormone replacement therapy, and risk of future cardiovascular events. J Am Coll Cardiol 2008; 52:124-131. (Pubitemid 351885446)
124. Stojanovic ND, Kwong P, Byrne DJ, et al. The effects of transdermal estradiol alone or with cyclical dydrogesterone on markers of cardiovascular disease risk in postmenopausal women with type 2 diabetes: a pilot study. Angiology 2003; 54:391-399. (Pubitemid 36935352)
125. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. J Am Med Assoc 1998; 280:605-613.
126. Manson JE, Hsia J, Johnson KC, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003; 349:523-534. (Pubitemid 36951364)
127. Hartgens F, Rietjens G, Keizer HA, et al. Effects of androgenic-anabolic steroids on apolipoproteins and lipoprotein (a). Br J Sports Med 2004; 38:253-259. (Pubitemid 38748112)
128. Kostner KM, Kostner GM. Therapy of hyper-Lp(a). Handb Exp Pharmacol 2005; 519-536.
129. Pearce EN. Hypothyroidism and dyslipidemia: modern concepts and approaches. Curr Cardiol Rep 2004; 6:451-456.
130. Grover GJ, Mellstrom K, Malm J. Therapeutic potential for thyroid hormone receptor-beta selective agonists for treating obesity, hyperlipidemia and diabetes. Curr Vasc Pharmacol 2007; 5:141-154.
131. Marcovina SM, Koschinsky ML, Albers JJ, Skarlatos S. Report of the National Heart, Lung, and Blood Institute Workshop on Lipoprotein(a) and Cardiovascular Disease: recent advances and future directions. Clin Chem 2003; 49:1785-1796.
132. Hackam DG, Anand SS. Emerging risk factors for atherosclerotic vascular disease: a critical review of the evidence. J Am Med Assoc 2003; 290:932-940.